Update
$Hologic(HOLX.US$ Bayer and Hologic Collaborating to Deliver Contrast-Enhanced Mammography 3 MINUTES AGO, 2:07 PM EDT VIA BUSINESSWIRE Collaboration Includes Robust Education and Training to Support Radiologists and Imaging Specialists Bayer and Hologic, Inc. (NASDAQ:HOLX) today announced a first-of-its-kind collaboration to deliver a coordinated solution for contrast-enhanced mammography (CEM). The two companies will showcase the solution at the annual Society of Breast Imaging Symposium from April 11-14, 2024 in Montreal, Canada. Contrast-enhanced mammography is a sensitive and relatively low-cost breast imaging modality that can be used to support breast cancer diagnosis and help to guide treatment.1 The offering brings together Hologic's leading mammography technologies and Bayer's leading contrast-enhanced mammography contrast delivery system, the MEDRAD® Stellant FLEX Computed Tomography (CT) Injection System. The MEDRAD Stellant FLEX CT Injection System with Certegra® Workstation is the first and only CT injection system 510(k) cleared with an additional contrast-enhanced mammography application. By working together, Hologic and Bayer are streamlining the purchasing process for radiologists and imaging facilities, providing a seamless set-up and ongoing, supportive educational resources. "We are thrilled to work with Hologic to increase access to this emerging breast imaging modality," said Sven Schmidt, Head of Region Americas Radiology at Bayer. "Together we will deliver an innovative and coordinated solution for both patients and healthcare professionals alike."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
